Roles of tumor suppressors in regulating tumor-associated inflammation

Cell Death and Differentiation

Volumn 21, Issue 11, 2014, Pages 1677-1686

  Yang, L ^a   Karin, M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; INFLAMMATION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NEOPLASM; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INFLAMMATION; MICE; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84919398687     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.131     Document Type: Review

References (122)

1. Sherr CJ. Principles of tumor suppression. Cell 2004; 116: 235-246.
2. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137.
3. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137: 609-622.
4. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994; 107: 369-378.
5. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993; 104: 1633-1639.
6. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000; 60: 3333-3337.
7. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53 and vascularendothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000; 89: 51-62.
8. Monnier Y, Zaric J, Ruegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy 2005; 4: 31-38.
9. Salvado MD, Alfranca A, Haeggstrom JZ, Redondo JM. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. TrendsMol Med 2012; 18: 233-243.
10. Lee TL, Yang XP, Yan B, Friedman J, Duggal P, Bagain L et al. A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007; 13: 5680-5691.
11. Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 2006; 66: 6622-6627.
12. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S et al. Mutant p53 prolongs nf-kappab activation and promotes chronic inflammation and inflammationassociated colorectal cancer. Cancer Cell 2013; 23: 634-646.
13. Shaked H, Hofseth LJ, Chumanevich A, Chumanevich AA, Wang J, Wang Y et al. Chronic epithelial NF-kappaB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci USA 2012; 109: 14007-14012.
14. Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L et al. Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res 2008; 68: 7130-7136.
15. Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG et al. p53 is a suppressor of inflammatory response in mice. FASEB J 2005; 19: 1030-1032.
16. Ruzankina Y, Schoppy DW, Asare A, Clark CE, Vonderheide RH, Brown EJ. Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat Genet 2009; 41: 1144-1149.
17. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013; 23: 93-106.
18. Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE et al. Non-cellautonomous tumor suppression by p53. Cell 2013; 153: 449-460.
19. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-660.
20. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
21. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-713.
22. Lu H, Yang X, Duggal P, Allen CT, Yan B, Cohen J et al. 2011TNF-alpha promotes c-REL/DeltaNp63alpha interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. Cancer Res 71: 6867-6877.
23. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008; 22: 2677-2691.
24. Yang X, Lu H, Yan B, Romano RA, Bian Y, Friedman J et al. DeltaNp63 versatilely regulates a broad NF-kappaB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res 2011; 71: 3688-3700.
25. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014; 14: 359-370.
26. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
27. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
28. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
29. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263-1271.
30. Amos-Landgraf JM, Irving AA, Hartman C, Hunter A, Laube B, Chen X et al. Monoallelic silencing and haploinsufficiency in early murine intestinal neoplasms. Proc Natl Acad Sci USA 2012; 109: 2060-2065.
31. Bilger A, Shoemaker AR, Gould KA, Dove WF. Manipulation of the mouse germline in the study of Min-induced neoplasia. Semin Cancer Biol 1996; 7: 249-260.
32. Merritt AJ, Gould KA, Dove WF. Polyclonal structure of intestinal adenomas in ApcMin/\+ mice with concomitant loss of Apc\+ from all tumor lineages. Proc Natl Acad Sci USA 1997; 94: 13927-13931.
33. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D et al. Adenomalinked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-258.
34. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 2012; 9: 561-570.
35. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13: 283-296.
36. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
37. Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS et al. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 2012; 31: 3322-3332.
38. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaBcytokine network. Cancer discovery 2011; 1: 158-169.
39. Wallace JA, Li F, Leone G, Ostrowski MC. Pten in the breast tumor microenvironment: modeling tumor-stroma coevolution. Cancer Res 2011; 71: 1203-1207.
40. Hanahan DWRA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
41. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004; 431: 405-406.
42. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
43. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8: 180-192.
44. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
45. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
46. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-527.
47. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007; 13: 944-951.
48. Zhang W, Kater AP, Widhopf GF 2nd, Chuang HY, Enzler T, James DF et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2010; 107: 18956-18960.
49. Weinberg RA. Coevolution in the tumor microenvironment. Nat Genet 2008; 40: 494-495.
50. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002; 32: 355-357.
51. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007; 357: 2543-2551.
52. Campbell IG, Qiu W, Polyak K, Haviv I. Breast-cancer stromal cells with TP53 mutations. N Engl J Med 2008 author reply 358: 1634-1635.
53. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008; 40: 650-655.
54. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005; 123: 1001-1011.
55. Svensson RU, Haverkamp JM, Thedens DR, Cohen MB, Ratliff TL, Henry MD. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol 2011; 179: 502-512.
56. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009; 461: 1084-1091.
57. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol 2012; 14: 159-167.
58. Achyut BR, Bader DA, Robles AI, Wangsa D, Harris CC, Ried T et al. Inflammationmediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling. PLoS Genet 2013; 9: e1003251.
59. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-851.
60. Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med 2011; 17: 1504-1508.
61. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464: 302-305.
62. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011; 12: 715-723.
63. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
64. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296.
65. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462: 104-107.
66. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
67. Murphy SH, Suzuki K, Downes M, Welch GL, De Jesus P, Miraglia LJ et al. Tumor suppressor protein (p)53, is a regulator of NF-kappaB repression by the glucocorticoid receptor. Proc Natl Acad Sci USA 2011; 108: 17117-17122.
68. Wang J, An H, Mayo MW, Baldwin AS, Yarbrough WG. LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 2007; 12: 239-251.
69. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL et al. Nuclear cytokineactivated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007; 446: 690-694.
70. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM et al. Tumourinfiltrating regulatory T cells stimulate mammary cancer metastasis through RANKLRANK signalling. Nature 2011; 470: 548-553.
71. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801-805.
72. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000; 25: 160-165.
73. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665-677.
74. Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 2012; 21: 738-750.
75. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011; 19: 629-639.
76. Fukuda A, Wang SC, JPt Morris, Folias AE, Liou A, Kim GE et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011; 19: 441-455.
77. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G et al. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006; 126: 489-502.
78. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011; 19: 456-469.
79. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 2013; 23: 107-120.
80. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T et al. Hepatocyte IKKbeta/NFkappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010; 17: 286-297.
81. Li Y, de Haar C, Peppelenbosch MP, van der Woude CJ. SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer. Cytokine Growth Factor Rev 2012; 23: 127-138.
82. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003; 4: 540-545.
83. Ogata H, Chinen T, Yoshida T, Kinjyo I, Takaesu G, Shiraishi H et al. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 2006; 25: 2520-2530.
84. Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA 2008; 105: 2445-2450.
85. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M et al. Abrogation of TGFbeta signaling in mammary carcinomas recruits Gr-1\+CD11b\+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35.
86. Yang L. TGFbeta and cancer metastasis: an inflammation link. Cancer Metastasis Rev 2010; 29: 263-271.
87. Kitamura T, Kometani K, Hashida H, Matsunaga A, Miyoshi H, Hosogi H et al. SMAD4-deficient intestinal tumors recruit CCR1(\+) myeloid cells that promote invasion. Nat Genet 2007; 39: 467-475.
88. Kim BG, Li C, Qiao W, Mamura M, Kasprzak B, Anver M et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 2006; 441: 1015-1019.
89. Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine. Immunity 2011; 35: 123-134.
90. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW et al. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett 2009; 283: 29-35.
91. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8: 1369-1375.
92. Monteleone G, Mann J, Monteleone I, Vavassori P, Bremner R, Fantini M et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem 2004; 279: 3925-3932.
93. Hong S, Lee C, Kim SJ. Smad7 sensitizes tumor necrosis factor induced apoptosis through the inhibition of antiapoptotic gene expression by suppressing activation of the nuclear factor-kappaB pathway. Cancer Res 2007; 67: 9577-9583.
94. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, Iritani BM. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res 2006; 66: 828-838.
95. Engle SJ, Ormsby I, Pawlowski S, Boivin GP, Croft J, Balish E et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 2002; 62: 6362-6366.
96. Lu T, Tian L, Han Y, Vogelbaum M, Stark GR. Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc Natl Acad Sci USA 2007; 104: 4365-4370.
97. Lu SL, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M et al. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 2004; 64: 4405-4410.
98. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A et al. Abrogation of TGFbeta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 2009; 119: 1571-1582.
99. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13: 206-220.
100. Pang Y, Gara SK, Achyut BR, Li Z, Yan HH, Day CP et al. Transforming growth factor beta signaling in myeloid cells is required for tumor metastasis. Cancer discovery 2013; 3: 936-951.
101. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
102. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19: 1264-1272.
103. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
104. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
105. Ferris RL, Grandis JR. NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13: 5663-5664.
106. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 2005; 25: 10097-10110.
107. Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 2012; 30: 2844-2852.
108. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
109. Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 2006; 66: 6622-6627.
110. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013; 23: 93-106.
111. Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE et al. Non-cellautonomous tumor suppression by p53. Cell 2013; 153: 449-460.
112. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005; 123: 1001-1011.
113. Chien WM, Garrison K, Caufield E, Orthel J, Dill J, Fero ML. Differential gene expression of p27Kip1 and Rb knockout pituitary tumors associated with altered growth and angiogenesis. Cell Cycle 2007; 6: 750-757.
114. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D et al. Adenomalinked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-258.
115. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaBcytokine network. Cancer Discov 2011; 1: 158-169.
116. Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS et al. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 2012; 31: 3322-3332.
117. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009; 461: 1084-1091.
118. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M et al. Abrogation of TGFbeta signaling in mammary carcinomas recruits Gr-1\+CD11b\+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35.
119. Yang L. TGFbeta and cancer metastasis: an inflammation link. Cancer Metastasis Rev 2010; 29: 263-271.
120. Achyut BR, Bader DA, Robles AI, Wangsa D, Harris CC, Ried T et al. Inflammationmediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling. PLoS Genet 2013; 9: e1003251.
121. Kitamura T, Kometani K, Hashida H, Matsunaga A, Miyoshi H, Hosogi H et al. SMAD4-deficient intestinal tumors recruit CCR1(\+) myeloid cells that promote invasion. Nat Genet 2007; 39: 467-475.
122. Kim BG, Li C, Qiao W, Mamura M, Kasprzak B, Anver M et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 2006; 441: 1015-1019.